Search Scholars Central
Articles, journals and conferences in one search. An exact title, DOI or ISSN is listed first.
Advanced searchHide advanced search
In the search box: "exact phrase" · -leave out · OR · prefix* · title: author: journal:
Perspective · 7 Dec 2022 Conference abstract · 18 Oct 2017 Aberrant genome duplication as both a cause and a cure for cancer
occur during proliferation of the cells that give rise to and maintain tissues. Cancer driver mutations initiate carcinogenesis, but genome destabilizing mutations promote aneuploidy, which contributes to tumor…
Conference abstract · 2018 Alternative splicing in diabetic nephropathy and other chronic kidney diseases
splicing (AS) has emerged in the post-genomic era as one of the main drivers of proteome diversity with at least 94% of multi-exon genes being alternatively spliced ... isoforms (or novel isoforms) in disease compared…
Conference abstract · 6 May 2019 Advances in diagnostics in lung cancer
advent of better understanding of the biology of lung cancer, especially underlying oncogenic driver mutations, the hunt to develop targets to these mutations has increased manifold. This ... actionable mutations like…
Conference abstract · 6 May 2019 Advances in diagnostics in lung cancer
advent of better understanding of the biology of lung cancer, especially underlying oncogenic driver mutations, the hunt to develop targets to these mutations has increased manifold. This ... actionable mutations like…
Conference abstract · 5 Oct 2018 Highway to personalized medicine: For NSCLC patients
most common subtype of lung cancer has impressively high number of discovered actionable driver mutation genes compare to other type of cancer. Historically, patients with NSCLC were commonly treated with…
Conference abstract · 21 May 2018 The possible role of cytochrome P450s in non-small cell lung cancer therapy
about 88 % of all lung cancer cases. NSCLC can be further defined by recurrent driver mutations. The most common mutations are KRAS and EGFR. Susceptiblity to lung cancer
Conference abstract · 13 Nov 2017 3D heat maps of cancer mutations in the mitochondrial electron transport system to identify driver domain candidates
protein domains are selected for somatic missense mutations during tumorigenesis, we created the 3D protein heatmap to identify potential cancer driver domains. A structural analysis via homology modeling allows…
Conference abstract · 9 Jan 2017 Genomic analysis of intra-tumor heterogeneity unveil cancer evolution
terms of tumor progression. Such neutral mutations are called âÂ?Â?passenger mutationsâÂ?, to distinguish them from the âÂ?Â?driver mutationsâÂ? that actively promote tumor cell proliferation. This ... therapeutic…
Perspective · 31 Mar 2025 Molecular and Genetic Insights into Primary Bone Tumors
Primary bone tumors encompass a heterogeneous group of neoplasms, ranging from benign
Conference abstract · 18 Jul 2018 A review of driver genetic alterations in thyroid cancers
cancer genome have been involved in development of the cancer and just driver mutations are concerned in tumor initiation. By way of illustrations, MAPK pathway which is motivated by BRAFV600E ... suggesting driver…
Mini review · 23 Jun 2023 Predicting the Prognosis and Survival in Early-Stage Lung Cancer after Curative Surgery
type, adenocarcinoma was the commonest among Asian population, with EGFR mutation being the commonest driver mutation. Various clinic-pathological factors were reported to be associated with the prognosis of early
Conference abstract · 12 Mar 2018 Understanding RNA editing in human cancer: Causes and functional consequences
Conventionally, cancer is driven by a clonal accumulation of somatic mutations, referred to as driver mutations, conferring a selective growth advantage to cancer cells. RNA editing, is an epigenetic mechanism
Research article · 2014 The EGFR and KRAS Mutation Status and Correlations with the Prevalence of Bone Metastases - The Results of Three Year Retrospective Analysis
become increasingly important in the prediction of chemotherapy sensitivity and mutation analysis to identify driver mutations as important targets of new therapeutic agents. These agents give an opportunity to provide
Conference abstract · 19 Dec 2018 Regulatory RNA genes: could they be important to the histopathology of tumors?
lineage committed parent cells. Large numbers of mutations occur in tumors, but the precise driver mutations for each tumors type remain unclear. Some genome studies have documented some tumors type
Conference abstract · 1 Dec 2016 Precision medicine: Role of rare mutation in colorectal cancer
Background & Aim: Several driver mutations have been discovered in colorectal cancer (CRC) progression including KRAS and BRAF that have practical significant therapeutic and prognostic value. Whole exome sequencing
Conference abstract · 21 Oct 2013 The role of centrosomal protein TAX1BP2 in the pathogenesis of hepatocellular carcinoma
frequency mutations occurred within a gene. A complex pattern of intrinsic low frequency driver mutations in well-known tumor oncogenes may exist prior to treatment, resulting in resistance to targeted
Conference abstract · 1 Sep 2018 2nd International Conference on Gastroenterology and Urology: Classification of gastric carcinomas - Helge Waldum Norwegian - University of Science and Technology
Tumor mutation analyzes can guide the selection of treatment strategies , especially when there are driver mutations. Analyzes of mutations do not usually give indication of the origin cell
Editorial · 31 Aug 2023 Targeting the Achilles Heel: Cancer Drug Targets for Precision Therapies
validation of cancer drug targets require comprehensive genomic and proteomic analyses, uncovering key driver mutations, altered signaling pathways, and dysregulated cellular processes. Targeted therapies are designed…
Conference abstract · 3 Aug 2015 Mutational landscape of aggressive cutaneous squamous cell carcinoma
cSCC. We performed whole-exome sequencing on 39 cases of aggressive cSCC to identify driver mutations and potential therapeutic targets. Besides the well-known cancer-associated genes TP53, CDKN2A, NOTCH1
Short communication · 21 Sep 2020 Data-driven Protein Networks of Early Lung Adenocarcinomas Harboring EGFR Mutations
remains unclear how epidermal growth factor receptor EGFR major driver mutations (L858R or Ex19del) affect downstream molecular networks and pathways, which would influence treatment outcomes of NSCLC patients. Our…
Conference abstract · 17 Oct 2016 Comprehensive detection of expressed mutations by anchored multiplex PCR and next-generation sequencing
landscape of driver mutations in cancer encompasses many types of mutations occurring across many genes. These include copy number variants (CNVs), single nucleotide variants (SNVs), insertions and deletions (indels)…
Conference abstract · 3 Jan 2018 Targeted cancer gene sequencing identifies potential causative novel candidate mutations in colon carcinogenesis
alteration plays an important role in this disease. Much of the underlying genetic cancer driver mutations in sporadic colorectal cancer (CRC) have not been characterized by race. Here, we report
Conference abstract · 17 Oct 2016 Identification of tumor cellular origins by anchored multiplex PCR and next-generation sequencing
tumor-initiating cells have both been shown to uniquely influence the development of specific driver mutations. For example, lung cancer subtypes that arise from different anatomic locations exhibit distinct mutation
Conference abstract · 28 Sep 2015 The use of patient-derived 3D cell cultures in pre-clinical research
PD3DâÂ?¢ cultures, we applied cost-efficient benchtop sequencing and show the preservation of putative driver mutations found in the original tumor. IC50 data generated by automated 384-well based dose

